This guideline provides recommendations for the use of PET imaging in gliomas. The review
examines established clinical benefit in glioma patients of PET using glucose (18F-FDG) …

Glioblastoma (GBM) is the most common primary malignant brain tumor in adults.
Regardless of ideal multidisciplinary treatment, including maximal surgical resection …

Background The colony stimulating factor 1 receptor (CSF1R) ligands, CSF1 and interleukin-
34, and the KIT ligand, stem cell factor, are expressed in glioblastoma (GB). Microglia …

The management of patients with glioma usually requires multimodality treatment including
surgery, radiotherapy, and systemic therapy. Accurate neuroimaging plays a central role for …

Myeloid cells comprise the majority of immune cells in tumors, contributing to tumor growth
and therapeutic resistance. Incomplete understanding of myeloid cells response to tumor …

Background: Glioblastoma (GBM) is a highly aggressive cancer with poor prognosis that
needs better treatment modalities. Moreover, there is a lack of reliable biomarkers to predict …

Background and purpose Both stereotactic radiotherapy (SRT) and immune-or targeted
therapy play an increasingly important role in personalized treatment of metastatic disease …

Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS
tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy …

Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults, with a
median survival of 14.6 months. Recent efforts have focused on identifying clinically relevant …

Stereotactic radiosurgery (SRS), typically administered in a single session, is widely
employed to safely, efficiently, and effectively treat small intracranial lesions. However, for …